Fortis Capital Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Fortis Capital Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$517K	Buy	+4,731	New	+$490K	0.06%	242

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Fortis Capital Advisors's PPH Position: Q2 2026 in Review

Fortis Capital Advisors opened a new position in VanEck Pharmaceutical ETF (PPH) in Q2 2026: 4,731 shares worth $517K. The stake represents 0.06% of the portfolio and ranks #242 among its holdings.

148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Fortis Capital Advisors held 4,731 shares of VanEck Pharmaceutical ETF worth $517K as of Q2 2026.
VanEck Pharmaceutical ETF was a new Fortis Capital Advisors position in Q2 2026.
VanEck Pharmaceutical ETF made up 0.06% of Fortis Capital Advisors's portfolio in Q2 2026, its #242 holding.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Fortis Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.